| Age (median) | 15-50 (36) |
| Sex (M/F) | 256/261 |
| Performance status (0-1-2/3-4/NA) | 460/48/9 |
| Initial WBC count (109/L) (median) | 0.4-486 (13.5) |
| FAB classification (0/1/2/3/4/5/6/7/NA) | 31/111/154/44/69/88/9/6/5 |
| Karyotype | |
| Performed | 337 |
| Evaluable | 309 |
| Normal | 133 |
| Abnormal | 176 (57%) |
| Favorable | 47 |
| Intermediate | 93 |
| Unfavorable | 36 |
| Age (median) | 15-50 (36) |
| Sex (M/F) | 256/261 |
| Performance status (0-1-2/3-4/NA) | 460/48/9 |
| Initial WBC count (109/L) (median) | 0.4-486 (13.5) |
| FAB classification (0/1/2/3/4/5/6/7/NA) | 31/111/154/44/69/88/9/6/5 |
| Karyotype | |
| Performed | 337 |
| Evaluable | 309 |
| Normal | 133 |
| Abnormal | 176 (57%) |
| Favorable | 47 |
| Intermediate | 93 |
| Unfavorable | 36 |
Abbreviation: NA, not available.